Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;86(8):873-8.
doi: 10.1136/jnnp-2014-308826. Epub 2014 Nov 27.

CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis

Affiliations

CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis

V Fridman et al. J Neurol Neurosurg Psychiatry. 2015 Aug.

Abstract

Background: The international Inherited Neuropathy Consortium (INC) was created with the goal of obtaining much needed natural history data for patients with Charcot-Marie-Tooth (CMT) disease. We analysed clinical and genetic data from patients in the INC to determine the distribution of CMT subtypes and the clinical impairment associated with them.

Methods: We analysed data from 1652 patients evaluated at 13 INC centres. The distribution of CMT subtypes and pathogenic genetic mutations were determined. The disease burden of all the mutations was assessed by the CMT Neuropathy Score (CMTNS) and CMT Examination Score (CMTES).

Results: 997 of the 1652 patients (60.4%) received a genetic diagnosis. The most common CMT subtypes were CMT1A/PMP22 duplication, CMT1X/GJB1 mutation, CMT2A/MFN2 mutation, CMT1B/MPZ mutation, and hereditary neuropathy with liability to pressure palsy/PMP22 deletion. These five subtypes of CMT accounted for 89.2% of all genetically confirmed mutations. Mean CMTNS for some but not all subtypes were similar to those previously reported.

Conclusions: Our findings confirm that large numbers of patients with a representative variety of CMT subtypes have been enrolled and that the frequency of achieving a molecular diagnosis and distribution of the CMT subtypes reflects those previously reported. Measures of severity are similar, though not identical, to results from smaller series. This study confirms that it is possible to assess patients in a uniform way between international centres, which is critical for the planned natural history study and future clinical trials. These data will provide a representative baseline for longitudinal studies of CMT.

Clinical trial registration: ID number NCT01193075.

Keywords: GENETICS; NEUROGENETICS; NEUROPATHY.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of clinically determined Charcot-Marie-Tooth (CMT) subtypes.

References

    1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974;6:98–118. - PubMed
    1. Rossor AM, Polke JM, Houlden H, et al. . Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 2013;9:562–71. - PubMed
    1. Shy ME, Blake J, Krajewski K, et al. . Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005;64:1209–14. - PubMed
    1. Shy ME, Chen L, Swan ER, et al. . Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008;70:378–83. - PubMed
    1. Pareyson D, Reilly MM, Schenone A, et al. . Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011;10:320–8. - PMC - PubMed

Publication types

MeSH terms

Associated data